In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry
2018

Congress : ESC Congress

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardioversion and Defibrillation
  • Session type : Rapid Fire Abstracts
  • FP Number : 360

Authors : V Schirripa (Rome,IT), P Radic (Zagreb,HR), K Pieper (Durham,US), L Illingworth (London,GB), J Y Le Heuzey (Paris,FR), P Jansky (Prague,CZ), D A Fitzmaurice (Coventry,GB), S Connolly (Hamilton,CA), R Cappato (Milan,IT), J Camm (London,GB), D Atar (Oslo,NO), A K Kakkar (London,GB)

15 views

Authors:
V. Schirripa1 , P. Radic2 , K. Pieper3 , L. Illingworth4 , J.Y. Le Heuzey5 , P. Jansky6 , D.A. Fitzmaurice7 , S. Connolly8 , R. Cappato9 , J. Camm10 , D. Atar11 , A.K. Kakkar12 , 1G. B. Grassi Hospital, Department of Cardiology - Rome - Italy , 2University of Zagreb School of Medicine - Zagreb - Croatia , 3Duke Clinical Research Institute, Duke University Medical Center - Durham - United States of America , 4Thrombosis Research Institute - London - United Kingdom , 5Hôpital Européen Georges Pompidou, Université Paris Descartes, Department of Cardiology - Paris - France , 6Motol University Hospital, Department of Cardiovascular Surgery - Prague - Czech Republic , 7University of Warwick, Cardiorespiratory Primary Care - Coventry - United Kingdom , 8McMaster University, Department of Medicine - Hamilton - Canada , 9Istituto Clinico Humanitas, Arrhythmia and Electrophysiology Research Center - Milan - Italy , 10St George's University of London, Department of Clinical Cardiology - London - United Kingdom , 11Oslo University Hospital, Ulleval and University of Oslo, Division of Medicine - Oslo - Norway , 12University College London - London - United Kingdom ,

On behalf: the Garfield-AF Investigators

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 51-52

Introduction: In atrial fibrillation (AF), a strategy of rhythm control based on cardioversion, by restoring sinus rhythm, may reduce the risk of stroke/systemic embolization (SE) and improve quality of life. However, randomized trials conducted so far have failed to show a benefit of cardioversion on hard endpoints. This study aims to investigate the prevalence of cardioversion and its association with clinical outcomes in patients from GARFIELD-AF registry.

Methods: GARFIELD-AF is a prospective, global registry of patients with recent-onset (<6 weeks) non-valvular AF (NVAF). Patients were enrolled in 32 countries between 2010 and 2016, patients with paroxysmal AF were excluded from the analysis. Comparisons were made between those receiving cardioversion at baseline and patients who had no cardioversion. Clinical endpoints, evaluated over 1 year, were: all-cause mortality, stroke or systemic embolism (SE) and major bleeding. An adjusted Cox proportional hazard model was utilized.

Results: The study cohort consisted of 23,919 patients; 2856 received cardioversion (11.9%). Patients who were treated with cardioversion were younger (65.5±11.7 years vs 70.6±11.3 years; p≤0.001), had a shorter time since AF diagnosis (1.7±1.6 weeks vs 2.0±1.7 weeks; p≤0.001), and were more often treated in a cardiology setting (73.9% vs 63.5%; p≤0.001). Event rates per 100 person years (95% CI) for all-cause mortality were 3.26% (2.65–4.01) (n=89) for cardioversion vs 5.40% (5.09–5.76) (n=1072) for no cardioversion, (Fig.1); stroke/SE rate 0.96% (0.65–1.40) (n=26) for cardioversion and 1.48% (1.32–1.65) (n=291) no cardioversion and major bleed 0.66% (0.42–1.05) (n=18) cardioversion vs 0.93% (0.80–1.07) (n=183) no cardioversion. Adjusted hazard ratios (95% CI) for cardioversion were 0.69 (0.53–0.90) for all-cause mortality, 0.92 (0.58–1.44) for stroke/SE and 0.82 (0.46–1.47) for major bleed.

Conclusion: Data from GARFIELD-AF show that cardioversion is used in a minority of patients with recent onset, non-paroxysmal NVAF. Patients who receive cardioversion have a lower risk of major events than those who did not. Our results, after adjustment, support the findings from randomized clinical trials, which suggest that there is no additional risk associated with cardioversion.

Figure 1

Please login to My ESC

This content may be restricted, please sign in to check your access.

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are